Amon R. Wafelman

2.5k total citations · 1 hit paper
23 papers, 2.0k citations indexed

About

Amon R. Wafelman is a scholar working on Epidemiology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Amon R. Wafelman has authored 23 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 8 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Immunology. Recurrent topics in Amon R. Wafelman's work include Radiopharmaceutical Chemistry and Applications (7 papers), Medical Imaging Techniques and Applications (6 papers) and Cervical Cancer and HPV Research (5 papers). Amon R. Wafelman is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (7 papers), Medical Imaging Techniques and Applications (6 papers) and Cervical Cancer and HPV Research (5 papers). Amon R. Wafelman collaborates with scholars based in Netherlands, Czechia and United States. Amon R. Wafelman's co-authors include Jan W. Drijfhout, A. Rob P.M. Valentijn, Rienk Offringa, Gert Jan Fleuren, Gemma G. Kenter, Sjoerd H. van der Burg, Cornelis J.M. Melief, Jaap Oostendorp, Annelies P.G. Vloon and Dorien M. A. Berends-van der Meer and has published in prestigious journals such as New England Journal of Medicine, Blood and PLoS ONE.

In The Last Decade

Amon R. Wafelman

23 papers receiving 1.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

2009 803 citations Gemma G. Kenter, Marij J.P. Welters et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amon R. Wafelman Netherlands	14	1.4k	788	570	554	210	23	2.0k
Bernardetta Nardelli United States	23	1.8k 1.3×	500 0.6×	671 1.2×	261 0.5×	72 0.3×	41	2.8k
Jean Nichols United States	24	1.1k 0.8×	552 0.7×	638 1.1×	181 0.3×	66 0.3×	50	2.1k
Kenneth R. Schroer United States	15	399 0.3×	736 0.9×	324 0.6×	574 1.0×	141 0.7×	23	1.6k
Denis Hudrisier France	31	2.3k 1.6×	349 0.4×	530 0.9×	254 0.5×	25 0.1×	54	2.8k
Michelle M. van Rossum Netherlands	24	1.1k 0.8×	794 1.0×	449 0.8×	488 0.9×	80 0.4×	54	2.1k
Antonio Carúz Spain	23	803 0.6×	625 0.8×	450 0.8×	949 1.7×	22 0.1×	74	2.7k
Nathalie T. Joncker United States	12	1.8k 1.3×	732 0.9×	319 0.6×	228 0.4×	29 0.1×	16	2.1k
J G van de Winkel Netherlands	28	1.7k 1.2×	278 0.4×	1.1k 2.0×	308 0.6×	121 0.6×	38	3.0k
Hidekazu Shirota Japan	27	1.3k 0.9×	416 0.5×	556 1.0×	145 0.3×	95 0.5×	82	2.0k
Aifen Lin China	33	1.8k 1.3×	432 0.5×	398 0.7×	292 0.5×	38 0.2×	93	2.5k

Countries citing papers authored by Amon R. Wafelman

Since Specialization

Citations

This map shows the geographic impact of Amon R. Wafelman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amon R. Wafelman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amon R. Wafelman more than expected).

Fields of papers citing papers by Amon R. Wafelman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amon R. Wafelman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amon R. Wafelman. The network helps show where Amon R. Wafelman may publish in the future.

Co-authorship network of co-authors of Amon R. Wafelman

This figure shows the co-authorship network connecting the top 25 collaborators of Amon R. Wafelman. A scholar is included among the top collaborators of Amon R. Wafelman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amon R. Wafelman. Amon R. Wafelman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Brand, Ronald, Ewoud J. van Hoogdalem, R. Verrijk, et al.. (2020). Ototopical drops containing a novel antibacterial synthetic peptide: Safety and efficacy in adults with chronic suppurative otitis media. PLoS ONE. 15(4). e0231573–e0231573. 25 indexed citations

2.

Meij, Pauline, Inge Jedema, Menno A. W. G. van der Hoorn, et al.. (2012). Generation and administration of HA-1-specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study. Haematologica. 97(8). 1205–1208. 42 indexed citations

3.

Kenter, Gemma G., Marij J.P. Welters, A. Rob P.M. Valentijn, et al.. (2009). Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia. New England Journal of Medicine. 361(19). 1838–1847. 803 indexed citations breakdown →

4.

Melief, Cornelis J.M., Marij J.P. Welters, Margriet J. Löwik, et al.. (2008). Robust T-cell responses and clinical responses following long peptide vaccination against high risk HPV-16. 8. 2. 1 indexed citations

5.

Wafelman, Amon R.. (2008). Symposium report—Development of safe protein therapeutics: Pre-clinical, clinical and regulatory issues. European Journal of Pharmaceutical Sciences. 34(4-5). 223–225. 1 indexed citations

6.

Hende, Muriel van den, Mariëtte I.E. van Poelgeest, Jeanette M. van der Hulst, et al.. (2008). Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia. International Journal of Cancer. 123(1). 146–152. 34 indexed citations

7.

Kenter, Gemma G., Marij J.P. Welters, A. Rob P.M. Valentijn, et al.. (2008). Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity. Clinical Cancer Research. 14(1). 169–177. 246 indexed citations

8.

Marijt, Erik W.A., et al.. (2007). Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. Haematologica. 92(1). 72–80. 36 indexed citations

9.

Tjabringa, G. Sandra, Amon R. Wafelman, R. Verrijk, et al.. (2005). Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application. Peptides. 27(4). 649–660. 154 indexed citations

10.

Falkenburg, J.H. Frederik, Amon R. Wafelman, Peter Joosten, et al.. (1999). Complete Remission of Accelerated Phase Chronic Myeloid Leukemia by Treatment With Leukemia-Reactive Cytotoxic T Lymphocytes. Blood. 94(4). 1201–1208. 13 indexed citations

11.

Falkenburg, J.H. Frederik, Amon R. Wafelman, Peter Joosten, et al.. (1999). Complete Remission of Accelerated Phase Chronic Myeloid Leukemia by Treatment With Leukemia-Reactive Cytotoxic T Lymphocytes. Blood. 94(4). 1201–1208. 224 indexed citations

12.

Wafelman, Amon R., et al.. (1997). Renal excretion of iodine-131 labelledmeta-iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumours. European Journal of Nuclear Medicine and Molecular Imaging. 24(5). 544–552. 20 indexed citations

13.

Wafelman, Amon R., Cornelis A. Hoefnagel, R. A. A. Maes, & Jos H. Beijnen. (1997). Bioanalysis of radioiodine labelled meta-iodobenzylguanidine, its metabolites and free radioiodide in body fluids. European Journal of Pharmaceutical Sciences. 5(2). 97–108. 2 indexed citations

14.

Wafelman, Amon R., et al.. (1997). Renal excretion of iodine-131 labelled meta -iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumours. European Journal of Nuclear Medicine and Molecular Imaging. 24(5). 544–552. 7 indexed citations

15.

Hoefnagel, Cornelis A., et al.. (1996). Radiochemical Purity, at Expiry, and Radiochemical Stability of Iodine-131 Labelled Meta-iodobenzylguanidine Concentrates for Intravenous Infusion. Nuklearmedizin - NuclearMedicine. 35(4). 122–125. 6 indexed citations

16.

Wafelman, Amon R., et al.. (1995). Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance. Nuclear Medicine Communications. 16(9). 767–772. 18 indexed citations

17.

Wafelman, Amon R., Hilde Rosing, Cornelis A. Hoefnagel, et al.. (1994). High-performance liquid chromatographic determination of metaiodobenzylguanidine in whole blood and plasma of cancer patients. Journal of Pharmaceutical and Biomedical Analysis. 12(9). 1173–1179. 3 indexed citations

18.

Wafelman, Amon R., et al.. (1994). Synthesis, radiolabelling and stability of radioiodinated m-iodobenzylguanidine, a review. Applied Radiation and Isotopes. 45(10). 997–1007. 22 indexed citations

19.

Wafelman, Amon R., Cornelis A. Hoefnagel, & Jos H. Beijnen. (1993). Radiochemical stability during infusion of 131I-labelled metaiodobenzylguanidine for therapeutic use. Nuclear Medicine Communications. 14(1). 819–822. 14 indexed citations

20.

Wafelman, Amon R., et al.. (1993). High-performance liquid chromatographic determination of m-iodobenzylguanidine in urine of cancer patients. Journal of Chromatography B Biomedical Sciences and Applications. 622(1). 71–77. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact